DOCSLIB.ORG

SARS-Cov-2 Vaccine Development and How Brazil Is Contributing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Genetics and Molecular Biology, 44, 1(suppl 1), e20200320 (2021) Copyright © Sociedade Brasileira de Genética. DOI: https://doi.org/10.1590/1678-4685-GMB-2020-0320 Review Article COVID-19 – Special Issue SARS-CoV-2 vaccine development and how Brazil is contributing Alex I. Kanno1*, Mayra M.F. Barbosa1,2*, Luana Moraes1,2 and Luciana C.C. Leite1 1Instituto Butantan, Laboratório de Desenvolvimento de Vacinas, São Paulo, SP, Brazil. 2Universidade de São Paulo, Programa de Pós-Graduação Interunidades em Biotecnologia, São Paulo, Brazil. Abstract The SARS-CoV-2 coronavirus pandemic calls for coordinated efforts by the scientific community for the development of vaccines. The most advanced strategies have focused on modifications of technologies that were already under development for other viruses, such as SARS, MERS, and even Influenza. Classic and new technologies, such as inactivated and attenuated viruses (non-replicative and replicative), DNA and mRNA vaccines, and nanoparticles containing SARS-CoV-2 antigens, are some of the strategies currently investigated. Although there is a very high expectation for the effectiveness of the most advanced vaccine candidates, there are still no established correlates of protection. Previous experience in vaccine development for other pathogens shows that differences in vaccine formulation can result in diverse immune responses and consequently, different protective properties. Therefore the importance of continuing investigations on a broad range of strategies. Expertise in vaccine development in Brazil was refocused to the new coronavirus. Impressive collaboration between institutions will support further developments until we have available a safe, effective, and economically viable vaccine. Established competence and collaborations will allow preparedness for future challenges and can also be used to address local issues as neglected infectious diseases. Keywords: SARS-CoV-2, vaccine, immunization strategies. Received: September 03, 2020; Accepted: February 19, 2021. Importance of vacines in disease control effective vaccine against SARS-CoV-2 and protect against Vaccination is one of the most important human the COVID-19 disease, have driven many collaborations, achievements in biomedical sciences. It has successfully along with unprecedented governmental support, leading to reduced the burden of infectious diseases worldwide. hundreds of strategies in pre-clinical and clinical evaluations According to the World Health Organization (WHO), the and so far, eight vaccine candidates are in phase III clinical benefits of vaccination go beyond the individual protection trials, the last before registration (WHO, 2020a). provided by the vaccine against the targeted pathogen. The race for vaccine development Ideally, it targets the complete eradication of the pathogen so it cannot re-emerge. The eradication of smallpox allowed The outbreak of COVID-19 has led to a global race the discontinuation of routine immunization. Furthermore, for the development of vaccines and treatments in record vaccination can be used to control mortality, morbidity, and time. The initiatives involve hundreds of countries, public- mitigate disease severity (Greenwood, 2014). Other advantages private partnerships, multinational pharmaceuticals, and include the protection of the non-vaccinated population (herd biotech companies. The Landscape of COVID-19 candidate immunity), against related and unrelated diseases, healthcare vaccines as of 12 November 2020 reports 48 candidates savings, prevention of antibiotic resistance, and extension of in clinical trials (Table 1) and 164 others in the preclinical life expectancy (Andre et al., 2008). stage. Different websites, (WHO, 2020a), (Milken Institute, The first cases of an “unknown cause” of pneumonia 2020) and others, provide updated information on the were reported in December 2019, to the WHO office in vaccines in development as they progress into clinical trials. China. By January, it had been identified as a new coronavirus In general, vaccine development undergoes several (SARS-CoV-2, leading to COVID-19 disease) and crossed steps: discovery, pre-clinical tests, and clinical trials, the Chinese borders. It was declared a pandemic in March. subdivided into phases I, II, and III, registration and phase The rate at which the SARS-CoV-2 virus spread through the IV (Figure 1). The discovery phase comprises the choice world and shutdown country borders, industries and local of the platform, design of targets, preparation of small businesses, only reinforces the importance of vaccines in batches, and in vitro testing. The pre-clinical stage involves disease control. The cost-effectiveness of a vaccine in this target validation in vivo from mice to non-human primates scenario is indisputable. The worldwide efforts to develop an (toxicity, immune response, safety, and protection). Finally, the vaccine candidate is tested in human subjects in clinical Send correspondence to Luciana C. C. Leite. Instituto Butantan, trials. In phase I, safety is evaluated in a small group of Laboratório de Desenvolvimento de Vacinas, São Paulo, SP, Brazil. E-mail: [email protected]. healthy volunteers; in phase II, safety and immunogenicity are evaluated in a few hundreds of healthy volunteers; and in *These authors have contributed equally. phase III, safety and efficacy are evaluated in thousands of 2 Table 1 – Vaccine candidates currently in Clinical trials. General safety Vaccine platform Name Institution Country Route Details of platform Clinical Stage Trial number and Advantages NCT04456595 CoronaVac Sinovac Biotech China i.m. Ph III NCT04582344 Sinopharm/ BBIBP-CorV China i.m. Ph III ChiCTR2000034780 Beijing Institute Inactivated vaccines Sinopharm/ Unnamed China i.m. used throughout the world Ph III ChiCTR2000034780 Wuhan Institute with a generally excellent The SARS-CoV-2 BBV152 Bharat Biotech India i.m. safety profile. Ph III CTRI/2020/11/028976 Inactivated virus virus inactivation Chinese Acad. Of Unnamed (Yunnan) China i.m. + adjuvant. Ph I/II NCT04470609 Medical Sciences Straightforward process; favorable safety and Research Institute tolerability profile QazCovid-in for Biological Kazakhstan i.m. Ph I/II NCT04530357 Safety Problems Beijing Minhai Unnamed China i.m. Ph I/II ChiCTR2000039462 Biotech Co Ltd AZD1222 Oxford/Astra Zeneca UK i.m. Ph III ISRCTN89951424 i.m./ Ph III NCT04526990 Ad5-nCov CanSino Biological China mucosal In general, safe and well Ph I NCT04552366 tolerated; concerns for Gamaleya Research Gam-COVID-Vac Russia i.m. Different Adenovirus immunocompromised Ph III NCT04530396 Institute expr. S glycoprotein individuals. Janssen ChAdOx1 (Chimp Ad26.COV2-S USA i.m. Ph III NCT04505722 Pharmaceutical – Oxford), Ad5 Vector used in gene therapy Non-replicating viral vector Pasteur/Thera/ i.m. (CanSino), Ad26 (J&J), & vaccination. Ad5 and Ad26 GRAd-COV2 Italy Ph I NCT04528641 (Adenovirus and MVA) LEUKOCARE 1-dose RD-Ad5 (Altimune) – high titer stable stocks. Ad26 – low preexisting ImmunityBio hAd5-S-Fusion+N-ETSD USA s.c. antibodies to the vector. Ph I NCT04591717 & NantKwest VXA-CoV2-1 Vaxart USA oral Ph I NCT04563702 Safety attested by its Ludwig-Maximilians/ Attenuated poxvirus use as against smallpox. MVA-SARS-2-S Germany i.m. Ph I NCT04569383 Univ. of Munich expressing Spike High immunogenicity including in the lungs. Kanno et al . COVID-19 vaccineinBrazil Table 1 – Cont. General safety Vaccine platform Name Institution Country Route Details of platform Clinical Stage Trial number and Advantages Beijing Wantai Flu-based vaccine In general, safe DelNS1-2019-nCoV-RBD-OPT1 Biological Pharmacy/ China i.n. Ph II ChiCTR2000039715 expressing RBD and well tolerated Xiamen Univ. Israel Institute for rVSV-SARS-CoV-2-S Israel i.m. Severely attenuated. Ph I/II NCT04608305 Biological Research Vesicular Stomatitis Virus Replicating viral vector No prior immunity. Merck Sharp (VSV) expressing Spike V590 USA i.m. High protein expression Ph I NCT04569786 & Dohme/IAVI In general, safe and well Institut Pasteur/ Live-attenuated measles TMV-083 France i.m. tolerated. Vector tested Ph I NCT04497298 Themis Bioscience vaccine expr. Spike in chikungunya vaccine Inovio i.d. Plasmid/ Spike NCT04336410 INO-4800 USA Ph I/II Pharmaceuticals electro electroporation NCT04447781 Favorable safety Osaka Univ./ NCT04463472 AG0301-COVID19 Japan i.m. Plasmid/ Spike and tolerability profile. Ph I/II AnGes/Takara Bio No DNA vaccines currently NCT04527081 Cadila Healthcare in use in humans. DNA ZyCoV-D India i.d. Plasmid/ M protein Ph I/II CTRI/2020/07/026352 Limited South Fast design/manufacturing; GX-19 Genexine Consortium i.m. Plasmid/Spike Ph I/II NCT04445389 Korea no cold chain for storage/distribution. Plasmid/ Trim. Spike bacTRL-Spike Symvivo Canada oral Ph I NCT04334980 in Bifidobacterium RNA vaccine for Zika, CMV, Chikungunya well-tolerated. No RNA vaccines currently mRNA-1273 Moderna USA i.m.d mRNA mixed w/ LNP Ph III NCT04470427 in use in humans. Fast design and manufacturing i.m. BioNTech/Fosun Germany/ mRNA mixed BNT162 (prime/ Ph III NCT04368728 Pharma/Pfizer USA with lipoplex. RNA boost) CVnCoV Curevac Germany i.m. mRNA mixed w/ LNPs. Ph II NCT04515147 self-replicating mRNA ARCT-021 Arcturus/Duke-NUS USA i.m Ph I/II NCT04480957 expr. Spike in a LNP Imperial College Self-amplifying LNP-nCoVsaRNA UK i.m. Ph I ISRCTN17072692 London Spike mRNA PLA Acad of Mil Sci Unnamed China i.m. mRNA Ph I ChiCTR2000034112 / Walvax Biotech 3 4 Table 1 – Cont. General safety Vaccine platform
Recommended publications
  • What Do We Know About India's Covaxin Vaccine?

    What Do We Know About India's Covaxin Vaccine?

    FEATURE Tamil Nadu, India COVID-19 VACCINES [email protected] BMJ: first published as 10.1136/bmj.n997 on 20 April 2021. Downloaded from Cite this as: BMJ 2021;373:n997 http://dx.doi.org/10.1136/bmj.n997 What do we know about India’s Covaxin vaccine? Published: 20 April 2021 India has rapidly approved and rolled out Covaxin, its own covid-19 vaccine. Kamala Thiagarajan examines what we know so far. Kamala Thiagarajan freelance journalist Who developed Covaxin? cheapest purchased by any country in the world at 206 rupees per shot for the 5.5 million doses the Covaxin was developed by Indian pharmaceutical government currently has on order. The government company Bharat Biotech in collaboration with the has capped the price of the vaccine sold in the private Indian Council of Medical Research, a government market, with private hospitals able to charge up to funded biomedical research institute, and its 250 rupees.13 subsidiary the National Institute of Virology. Covaxin does not require storage at sub-zero Bharat Biotech has brought to market 16 original temperatures, which would be hard to maintain in vaccines, including for rotavirus, hepatitis B, Zika India’s climate and with the frequent power cuts in virus, and chikungunya.1 The company reportedly rural areas. Covaxin is available in multi-dose vials spent $60-$70m (£43-£50m; €50-€58m) developing and is stable at the 2-8°C that ordinary refrigeration Covaxin.2 can achieve. How does Covaxin work? Bharat Biotech says it has a stockpile of 20 million The vaccine is similar to CoronaVac (the Chinese doses of Covaxin for India and is in the process of vaccine developed by Sinovac)3 in that it uses a manufacturing 700 million doses at its four facilities complete infective SARS-CoV-2 viral particle in two cities by the end of the year.
  • Perspectives for Therapeutic HPV Vaccine Development Andrew Yang1†, Emily Farmer1†,T.C.Wu1,2,3,4 and Chien-Fu Hung1,4,5*

    Perspectives for Therapeutic HPV Vaccine Development Andrew Yang1†, Emily Farmer1†,T.C.Wu1,2,3,4 and Chien-Fu Hung1,4,5*

    Yang et al. Journal of Biomedical Science (2016) 23:75 DOI 10.1186/s12929-016-0293-9 REVIEW Open Access Perspectives for therapeutic HPV vaccine development Andrew Yang1†, Emily Farmer1†,T.C.Wu1,2,3,4 and Chien-Fu Hung1,4,5* Abstract Background: Human papillomavirus (HPV) infections and associated diseases remain a serious burden worldwide. It is now clear that HPV serves as the etiological factor and biologic carcinogen for HPV-associated lesions and cancers. Although preventative HPV vaccines are available, these vaccines do not induce strong therapeutic effects against established HPV infections and lesions. These concerns create a critical need for the development of therapeutic strategies, such as vaccines, to treat these existing infections and diseases. Main Body: Unlike preventative vaccines, therapeutic vaccines aim to generate cell-mediated immunity. HPV oncoproteins E6 and E7 are responsible for the malignant progression of HPV-associated diseases and are consistently expressed in HPV-associated diseases and cancer lesions; therefore, they serve as ideal targets for the development of therapeutic HPV vaccines. In this review we revisit therapeutic HPV vaccines that utilize this knowledge to treat HPV-associated lesions and cancers, with a focus on the findings of recent therapeutic HPV vaccine clinical trials. Conclusion: Great progress has been made to develop and improve novel therapeutic HPV vaccines to treat existing HPV infections and diseases; however, there is still much work to be done. We believe that therapeutic HPV vaccines have the potential to become a widely available and successful therapy to treat HPV and HPV-associated diseases in the near future.
  • An Update Review of Globally Reported SARS-Cov-2 Vaccines in Preclinical and Clinical Stages

    An Update Review of Globally Reported SARS-Cov-2 Vaccines in Preclinical and Clinical Stages

    International Immunopharmacology 96 (2021) 107763 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Review An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages Hamid Motamedi a, Marzie Mahdizade Ari b, Shirin Dashtbin b, Matin Fathollahi a, Hadi Hossainpour a, Amirhoushang Alvandi a,c, Jale Moradi a, Ramin Abiri a,d,* a Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran b Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran c Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran d Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran ARTICLE INFO ABSTRACT Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the rapidly spreading COVID-19 pandemic COVID-19 in the world. As an effective therapeutic strategy is not introduced yet and the rapid genetic SARS-CoV-2 variations in the virus, there is an emerging necessity to design, evaluate and apply effective new vaccines. An Vaccines acceptable vaccine must elicit both humoral and cellular immune responses, must have the least side effects and the storage and transport systems should be available and affordable for all countries. These vaccines can be classified into different types: inactivated vaccines, live-attenuated virus vaccines, subunit vaccines, virus-like particles (VLPs), nucleic acid-based vaccines (DNA and RNA) and recombinant vector-based vaccines (repli­ cating and non-replicating viral vector). According to the latest update of the WHO report on April 2nd, 2021, at least 85 vaccine candidates were being studied in clinical trial phases and 184 candidate vaccines were being evaluated in pre-clinical stages.
  • For Schools and Parents: K-12 Immunization Requirements

    For Schools and Parents: K-12 Immunization Requirements

    FOR SCHOOLS AND PARENTS: K-12 IMMUNIZATION REQUIREMENTS NJ Department of Health (NJDOH) Vaccine Preventable Disease Program Summary of NJ School Immunization Requirements Listed in the chart below are the minimum required number of doses your child must have to attend a NJ school.* This is strictly a summary document. Exceptions to these requirements (i.e. provisional admission, grace periods, and exemptions) are specified in the Immunization of Pupils in School rules, New Jersey Administrative Code (N.J.A.C. 8:57-4). Please reference the administrative rules for more details https://www.nj.gov/health/cd/imm_requirements/acode/. Additional vaccines are recommended by Advisory Committee on Immunization Practices (ACIP) for optimal protection. For the complete ACIP Recommended Immunization Schedule, please visit http://www.cdc.gov/vaccines/schedules/index.html. Minimum Number of Doses for Each Vaccine Grade/level child DTaP Polio MMR Varicella Hepatitis Meningococcal Tdap enters school: Diphtheria, Tetanus, acellular Pertussis Inactivated (Measles, (Chickenpox) B (Tetanus, Polio Vaccine Mumps, diphtheria, (IPV) Rubella) acellular pertussis) § | Kindergarten – A total of 4 doses with one of these doses A total of 3 2 doses 1 dose 3 doses None None 1st grade on or after the 4th birthday doses with one OR any 5 doses† of these doses given on or after the 4th birthday ‡ OR any 4 doses nd th † 2 – 5 grade 3 doses 3 doses 2 doses 1 dose 3 doses None See footnote NOTE: Children 7 years of age and older, who have not been previously vaccinated with the primary DTaP series, should receive 3 doses of Td.
  • Gamma-Irradiated SARS-Cov-2 Vaccine Candidate, OZG-38.61.3, Confers Protection from SARS-Cov-2 Challenge in Human ACEII-Transgen

    Gamma-Irradiated SARS-Cov-2 Vaccine Candidate, OZG-38.61.3, Confers Protection from SARS-Cov-2 Challenge in Human ACEII-Transgen

    www.nature.com/scientificreports OPEN Gamma‑irradiated SARS‑CoV‑2 vaccine candidate, OZG‑38.61.3, confers protection from SARS‑CoV‑2 challenge in human ACEII‑transgenic mice Raife Dilek Turan1,2,19, Cihan Tastan1,3,4,19*, Derya Dilek Kancagi1,19, Bulut Yurtsever1,19, Gozde Sir Karakus1,19, Samed Ozer5, Selen Abanuz1,6, Didem Cakirsoy1,8, Gamze Tumentemur7, Sevda Demir2, Utku Seyis1, Recai Kuzay1, Muhammer Elek1,2, Miyase Ezgi Kocaoglu1, Gurcan Ertop7, Serap Arbak9, Merve Acikel Elmas9, Cansu Hemsinlioglu1, Ozden Hatirnaz Ng10, Sezer Akyoney10,11, Ilayda Sahin8,12, Cavit Kerem Kayhan13, Fatma Tokat14, Gurler Akpinar15, Murat Kasap15, Ayse Sesin Kocagoz16, Ugur Ozbek12, Dilek Telci2, Fikrettin Sahin2, Koray Yalcin1,17, Siret Ratip18, Umit Ince14 & Ercument Ovali1 The SARS‑CoV‑2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A and smallpox proved to be reliable approaches for immunization for prolonged periods. In this study, a gamma‑irradiated inactivated virus vaccine does not require an extra purifcation process, unlike the chemically inactivated vaccines. Hence, the novelty of our vaccine candidate (OZG‑38.61.3) is that it is a non‑adjuvant added, gamma‑irradiated, and intradermally applied inactive viral vaccine. Efciency and safety dose (either 1013 or 1014 viral RNA copy per dose) of OZG‑38.61.3 was initially determined in BALB/c mice. This was followed by testing the immunogenicity and protective efcacy of the vaccine. Human ACE2‑encoding transgenic mice were immunized and then infected with the SARS‑CoV‑2 virus for the challenge test.
  • Main Outcomes of Discussion of WHO Consultation on Nucleic Acid

    Main Outcomes of Discussion of WHO Consultation on Nucleic Acid

    MAIN OUTCOMES OF DISCUSSION FROM WHO CONSULTATION ON NUCLEIC ACID VACCINES I. Knezevic, R. Sheets 21-23 Feb, 2018 Geneva, Switzerland CONTEXT OF DISCUSSION • WHO Consultation held to determine whether the existing DNA guidelines were due for revision or if they remained relevant with today’s status of nucleic acid vaccine development and maturity towards licensure (marketing authorization) • Presentation will cover alignment to existing guidelines • Current status of development of DNA and RNA vaccines, both prophylactic & therapeutic • Main outcomes of discussion • Next steps already underway & planned STATUS OF DEVELOPMENT OF NUCLEIC ACID VACCINES • First likely candidate to licensure could be a therapeutic DNA vaccine against Human Papilloma Viruses • Anticipated to be submitted for licensure in 3-5 years • Other DNA vaccines are likely to follow shortly thereafter, e.g., Zika prophylaxis • RNA vaccines – less clinical experience, but therapeutic RNAs anticipated in 2021/22 timeframe to be submitted for licensure • For priority pathogens in context of public health emergencies, several candidates under development (e.g., MERS-CoV, Marburg, Ebola) MAIN OUTCOMES - GENERAL • Regulators expressed need for updated DNA guideline for prophylaxis and therapy • Less need at present for RNA vaccines in guideline but need some basic PTC • Flexibility needed now until more experience gained for RNA vaccines that will come in next few years • Revisit need for a more specific guideline at appropriate time for RNA vaccines • Institutional Biosafety Committees are regulated by national jurisdictions & vary considerably • How can WHO assist to streamline or converge these review processes? Particularly, during Public Health Emergency – can anything be done beforehand? MAIN OUTCOMES - DEFINITIONS • Clear Definitions are needed • Proposed definition of DNA vaccine: • A DNA plasmid(s) into which the desired immunogen(s) is (are) encoded and prepared as purified plasmid preparations to be administered in vivo.
  • HPV Vaccine Safety - Vaccine Safety

    HPV Vaccine Safety - Vaccine Safety

    CDC - HPV Vaccine Safety - Vaccine Safety Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options CDC Home CDC 24/7: Saving Lives. Protecting People.™ Search The CDC Vaccine Safety Vaccine Safety Vaccines Safety Basics Diphtheria, Tetanus, and Pertussis Vaccines: DTaP, Td, and Tdap Haemophilus Influenzae Type B (Hib) Hib Summary Human Papillomavirus (HPV) FAQs about HPV Vaccine Safety FAQ: Gardasil Vaccine recall JAMA Report Summary Information from FDA and CDC on Gardasil and its Safety (Archived) Measles, Mumps, Rubella (MMR) MMR Vaccine Safety Studies Measles, Mumps, Rubella, Varicella (MMRV) Information on the VSD MMRV Vaccine Safety Study MMRV Vaccine Safety Studies MMRV and Febrile Seizures Rotavirus Varicella Addressing Common Concerns Adjuvants Autism Vaccine not associated with autism CDC Statement: 2004 Pediatrics Paper CDC Statement on Pandemrix Fainting (Syncope) FAQs about Fainting (Syncope) After Vaccination Childhood Vaccines and Febrile Seizures Influenza Season 2012-2013 Influenza Season 2010-2011 GBS GBS and Menactra Meningococcal Vaccine FAQs about GBS and Menactra Meningococcal Vaccine IOM Assessment of Studies on Childhood Immunization Schedule IOM Report on Adverse Effects of Vaccines Pregnancy and Influenza Vaccine Safety Sudden Infant Death Syndrome (SIDS) Thimerosal http://www.cdc.gov/vaccinesafety/vaccines/HPV/index.html[10/13/2014 5:59:00 PM] CDC - HPV Vaccine Safety - Vaccine Safety CDC Study on Thimerosal and Risk of Autism
  • Review of COVID-19 Vaccine Subtypes, Efficacy and Geographical Distributions Andre Ian Francis ‍ ‍ ,1 Saudah Ghany,1 Tia Gilkes,1 Srikanth Umakanthan2

    Review of COVID-19 Vaccine Subtypes, Efficacy and Geographical Distributions Andre Ian Francis ‍ ‍ ,1 Saudah Ghany,1 Tia Gilkes,1 Srikanth Umakanthan2

    Review Postgrad Med J: first published as 10.1136/postgradmedj-2021-140654 on 6 August 2021. Downloaded from Review of COVID-19 vaccine subtypes, efficacy and geographical distributions Andre Ian Francis ,1 Saudah Ghany,1 Tia Gilkes,1 Srikanth Umakanthan2 1Department of Clinical Medical ABSTRACT 2021, the Ad26.COV2.S, developed by Janssen Sciences, The Faculty of Medical As of 1 May 2021, there have been 152 661 445 (Johnson & Johnson) and Moderna on 30 April.4 Sciences, The University of the COVAX, coordinated by WHO, Gavi: The West Indies, St. Augustine, Covid-19 cases with 3 202 256 deaths globally. Trinidad and Tobago This pandemic led to the race to discover a vaccine Vaccine Alliance, the Coalition for Epidemic 2Pathology unit, Department to achieve herd immunity and curtail the damaging Preparedness Innovations (CEPI), acts as a of Paraclinical Sciences, The effects of Covid-19. This study aims to discuss the most programme that supports the development of University Of The West Indies, St. COVID-19 vaccine candidates and negotiates their Augustine, Trinidad and Tobago recent WHO-approved Covid-19 vaccine subtypes, their status and geographical scheduled updates as of 4 pricing to ensure low- and- middle- income countries have a fair shot at receiving vaccines.5 Correspondence to May 2021. The keywords “Covid-19, Vaccines, Pfizer, Mr. Andre Ian Francis, The BNT162b2, AstraZeneca, AZD1222, Moderna, mRNA- This article aims at discussing the most recent University of the West Indies, St. 1273, Janssen, Ad26.COV2.S” were typed into PubMed. WHO- approved COVID-19 vaccine subtypes, their Augustine, Trinidad and Tobago; Thirty Two relevant PubMed articles were included in status and geographical scheduled updates as of 4 andre.
  • (ACIP) General Best Guidance for Immunization

    (ACIP) General Best Guidance for Immunization

    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
  • A Step Towards Revising the Model for Vaccine Tuberculosis Immunity

    A Step Towards Revising the Model for Vaccine Tuberculosis Immunity

    COMMENTARY CONTEST Revising the model for vaccine development: a step towards tuberculosis immunity Amy Dagenais1 1University of Ottawa, Ottawa, Ontario, Canada Date Published: August 26, 2021 DOI: https://doi.org/10.18192/UOJM.V11iS1.5929 Keywords: Tuberculosis, COVID-19, vaccines hanks to accelerated vaccine development, the first with the largest infectious disease burden in the world, COVID-19 vaccine was approved for use by Health tolling 10 million new infections and 1.2 million deaths Canada only nine months after the disease was in 2019 alone.² Indeed, tuberculosis is one of the top 10 Tdeclared a pandemic by the World Health Organization.¹ causes of death worldwide—but the situation remains This unprecedented feat was made possible by three underdiscussed as most cases are recorded in developing critical factors: a stressed sense of urgency, substantial areas, such as South-East Asia (44%) and Africa (25%), or funding, and parallel pre-clinical and clinical trials. Such in underserved populations such as the Inuit in Canada.2,3 a concerted effort not only led to the development of Approximately one-quarter of the world population is multiple effective vaccines, but also bred innovation as infected by the etiological agent of tuberculosis: the mRNA technology bloomed despite its limited use in the bacterium Mycobacterium tuberculosis (Mtb), known as past. This success story paves the way for the accelerated the most successful human pathogen.² development of vaccines for other diseases, such as tuberculosis—the deadliest infectious disease of modern The intracellular pathogen has co-evolved with humans times before COVID-19 emerged. to evade host immune defenses, rendering TB treatment particularly difficult.
  • Updated May 26, 2021 Cross-Border Industry Partnerships on COVID-19 Vaccines and Therapeutics Vaccines • Curevac O Celonic Wi

    Updated May 26, 2021 Cross-Border Industry Partnerships on COVID-19 Vaccines and Therapeutics Vaccines • Curevac O Celonic Wi

    Updated May 26, 2021 Cross-Border Industry Partnerships on COVID-19 Vaccines and Therapeutics Vaccines • CureVac o Celonic will manufacture 100 million doses of CureVac’s vaccine at its plant in Heidelberg, Germany, providing bulk substance for 50 million doses by the end of 2021. (press release) o Novartis will manufacture CureVac’s vaccine. (press release) o GlaxoSmithKline plc and CureVac N.V. announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine. (press release) o Rentschler Biopharma SE will manufacture CureVac’s vaccine. (press release) o Bayer will support the further development, supply and key territory operations of CureVac’s vaccine candidate. (press release) o Fareva will dedicate a manufacturing plant in France to the fill and finish of CureVac’s vaccine. (press release) o Wacker Chemie AG will manufacture CureVac’s vaccine candidate at its Amsterdam site. (press release) o CureVac will collaborate with Tesla Grohmann Automation to develop an RNA printer that works like a mini-factory and can produce such drugs automatically. (press release) • Moderna o Samsung Biologics will provide large scale, commercial fill-finish manufacturing for Moderna’s vaccine in South Korea. (press release) o Baxter International will provide fill/finish services and supply packaging for Moderna. (press release) o Sanofi will manufacture 200 million doses of Moderna’s COVID-19 vaccine starting in September 2021. (press release) o Rovi will produce bulk substance for Moderna’s COVID-19 vaccine, expanding an agreement between the companies.
  • COVID-19 and Cancer: from Basic Mechanisms to Vaccine Development Using Nanotechnology

    COVID-19 and Cancer: from Basic Mechanisms to Vaccine Development Using Nanotechnology

    International Immunopharmacology 90 (2021) 107247 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Review COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology Hyun Jee Han a,*, Chinekwu Nwagwu b, Obumneme Anyim c, Chinedu Ekweremadu d, San Kim e a University College London, Department of Neonatology, United Kingdom b Department of Pharmaceutics, University of Nigeria Nsukka, Nigeria c Department of Internal Medicine, University of Nigeria Teaching Hospital Ituku-Ozalla, Enugu, Nigeria d Department of Pharmaceutics and Pharmaceutical Technology Enugu State University of Science and Technology, Nigeria e Basildon and Thurrock University Hospital, United Kingdom ARTICLE INFO ABSTRACT Keywords: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV- COVID-19 2), is a global pandemic which has induced unprecedented ramifications,severely affecting our society due to the Cancer long incubation time, unpredictably high prevalence and lack of effective vaccines. One of the interesting notions Vaccine development is that there is an association between COVID-19 and cancer. Cancer patients seem to exhibit exacerbated Pharmaceutics conditions and a higher mortality rate when exposed to the virus. Therefore, vaccines are the promising solution Nanotechnology to minimise the problem amongst cancer patients threatened by the new viral strains. However, there are still limitations to be considered, including the efficacy of COVID vaccines for immunocompromised individuals, possible interactions between the vaccine and cancer, and personalised medicine. Not only to eradicate the pandemic, but also to make it more effective for immunocompromised patients who are suffering from cancer, a successful vaccine platform is required through the implementation of nanotechnology which can also enable scalable manufacturing and worldwide distribution along with its faster and precise delivery.